Lijun Miao

First Affiliated Hospital of Zhengzhou University — China

Medicine · Health Sciences

6h-index135citations35works1.12yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(19), CAR-T cell therapy research(18), Immunotherapy and Immune Responses(6), Lung Cancer Treatments and Mutations(3), Cancer Research and Treatments(3)

Publications35 total

Prognostic Value of the Albumin Corrected Anion Gap in ICU Patients with Chronic Obstructive Pulmonary Disease and Sepsis: A MIMIC-IV Cohort Study

1 cited

International Journal of COPD·2025· 1 citedOpen Access

β-receptor blocker enhances anti-tumor immunity via inhibiting lactate-induced norepinephrine metabolism of macrophages during malignant pleural effusion

2 cited

Frontiers in Immunology·2025· 2 citedOpen Access

Table S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S2 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S5 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S4 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S2 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S6 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S4 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S1 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S3 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S6 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S3 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Table S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S1 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S9 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Data from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Figure S8 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

2024Open Access

Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC

14 cited

Journal for ImmunoTherapy of Cancer·2024· 14 citedOpen Access

page 1 of 2Next →

Frequent Co-authors

Qitai Zhao(19), Yi Zhang(19), Zhen Zhang(18), Xuan Zhao(18), Xinfeng Chen(18), Congcong Li(18), Yaqing Liu(18), Chunyi Shen(18), Lijie Song(18), Fuyou Guo(18), Jie Zhao(18), Weiyue Gu(18), Xiaoning Mou(17), Fengxiang Huang(2), Ruiping Qiao(2), Yongjun Wu(2), Horng‐Dar Wang(2), Feifei Fan(2), Jie Li(2), Kai Ma(1)